Condition: Atrial Fibrillation · Persistent Atrial Fibrillation · Paroxysmal AF · Sponsor: Boston Scientific Corporation
The objective of this feasibility study is to evaluate the safety and effectiveness of the FARAFLEX mapping and pulsed field ablation (PFA) catheter, a novel catheter in treating persistent atrial fibrillation (PersAF) or symptomatic Paroxysmal Atrial Fibrillation (PAF).
This description comes directly from the study's public registry record.
Sharda Mehta · 800-227-3422 · sharda.mehta@bsci.com
Maria Grazia Pietropaolo · +393463514999 · MariaGrazia.Pietropaolo@bsci.com
Always discuss trial participation with your own doctor first.
| UZ Brussel Hospital | Brussels, Belgium | Recruiting |
| Klinicki bolnicki centar Split | Split, Croatia | Recruiting |
| Nemocnice Na Homolce Hospital | Prague, Czechia | Recruiting |
| Fondazione PTV - Policlinico Tor Vergata | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06510556